ATE541847T1 - Pyrazolopyrimidine als natriumkanalblocker - Google Patents

Pyrazolopyrimidine als natriumkanalblocker

Info

Publication number
ATE541847T1
ATE541847T1 AT02792224T AT02792224T ATE541847T1 AT E541847 T1 ATE541847 T1 AT E541847T1 AT 02792224 T AT02792224 T AT 02792224T AT 02792224 T AT02792224 T AT 02792224T AT E541847 T1 ATE541847 T1 AT E541847T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidines
compositions
methods
sodium channel
channel blockers
Prior art date
Application number
AT02792224T
Other languages
English (en)
Inventor
Robert Atkinson
Michael Gross
Rhee Michiel Van
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Application granted granted Critical
Publication of ATE541847T1 publication Critical patent/ATE541847T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02792224T 2001-11-01 2002-11-01 Pyrazolopyrimidine als natriumkanalblocker ATE541847T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33587401P 2001-11-01 2001-11-01
PCT/US2002/035171 WO2003037900A2 (en) 2001-11-01 2002-11-01 Pyrazolopyrimidines

Publications (1)

Publication Number Publication Date
ATE541847T1 true ATE541847T1 (de) 2012-02-15

Family

ID=23313580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792224T ATE541847T1 (de) 2001-11-01 2002-11-01 Pyrazolopyrimidine als natriumkanalblocker

Country Status (5)

Country Link
US (2) US6833371B2 (de)
EP (1) EP1506196B1 (de)
AT (1) ATE541847T1 (de)
CA (1) CA2465326C (de)
WO (1) WO2003037900A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20021067A3 (cs) * 1999-09-30 2002-11-13 Neurogen Corporation Určité alkylendiaminové substituované pyrazolo[1,5-a]- 1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
ATE345344T1 (de) * 2001-03-27 2006-12-15 Neurogen Corp (oxopyrazolo 1,5aöpyrimidin-2-yl) alkylcarbonsäureamide
EP1430032A2 (de) * 2001-09-24 2004-06-23 Elan Pharmaceuticals, Inc. Substituierte amide für die behandlung von neurologischen erkrankungen
US6770484B2 (en) * 2001-11-29 2004-08-03 Dong C. Liang Using flame and graphite furnace atomic absorption spectrometry for analysis of sodium channel activity
AU2002367023A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2004024066A2 (en) * 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
US20040085904A1 (en) * 2002-10-31 2004-05-06 Bordogna Mark A. Method for flow control of packets aggregated from multiple logical ports over a transport link
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
WO2004087956A2 (en) * 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Cell lines for the functional expression of nav1.8
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
EP1782859A3 (de) * 2003-04-11 2009-09-30 High Point Pharmaceuticals, LLC Pharmazeutische Verwendung von Pyrazolo [1,5- a] Pyrimidin-Derivaten
MXPA06001494A (es) 2003-08-05 2007-05-11 Vertex Pharma Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension.
WO2005030773A1 (ja) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. 新規ピラゾロピリミジン誘導体
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
US20060258713A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of pain
US20090131412A1 (en) * 2005-06-07 2009-05-21 Dainippon Sumitomo Pharma Co., Ltd. Novel 2-quinolone derivative
EP1926734A1 (de) 2005-08-22 2008-06-04 Amgen Inc. Als modulatoren von kinaseenzymen geeignete pyrazolopyridin- und pyrazolopyrimidinverbindungen
EA200801492A1 (ru) * 2005-11-01 2008-10-30 Транстек Фарма Фармацевтическое применение замещенных амидов
CA2648074A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
US20090306048A1 (en) * 2006-06-16 2009-12-10 John Paul Kilburn Pharmaceutical use of substituted piperidine carboxamides
WO2008006702A1 (en) 2006-07-13 2008-01-17 High Point Pharmaceuticals, Llc. 11beta-hydroxysteroid dehydrogenase type 1 active compounds
AU2007280428B2 (en) 2006-08-04 2012-04-12 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
ES2359447T3 (es) * 2006-08-04 2011-05-23 MERZ PHARMA GMBH & CO. KGAA Pirazolopirimidinas sustituidas, un proceso para su preparación y su uso como medicina.
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP2010043004A (ja) * 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
JP5243455B2 (ja) 2007-02-23 2013-07-24 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規化合物
EP2129652A2 (de) 2007-02-23 2009-12-09 High Point Pharmaceuticals, LLC N-adamantylbenzamide als inhibitoren von 11-beta-hydroxysteroiddehydrogenase
WO2008110196A1 (en) 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
ES2393230T3 (es) 2007-04-24 2012-12-19 High Point Pharmaceuticals, Llc Uso farmacéutico de amidas sustituidas
PL2197280T3 (pl) 2007-08-27 2013-11-29 Basf Se Związki pirazolowe do zwalczania szkodników będących bezkręgowcami
WO2009051827A1 (en) * 2007-10-18 2009-04-23 The United States Of America As Represented By The Department Of Veterans Affairs Modulation of sodium channels by nicotinamide adenine dinucleotide
US9114151B2 (en) * 2007-10-18 2015-08-25 The United States Of America Dept. Of Veterans Affairs Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
US9211301B2 (en) 2007-10-18 2015-12-15 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
US9220720B2 (en) 2007-10-18 2015-12-29 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
US9050350B2 (en) 2007-10-18 2015-06-09 U.S. Department Of Veterans Affairs Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
EP2085398A1 (de) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
EP2090576A1 (de) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-Pyrazolo[1,5-a]pyridin-Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Modulatoren des Metabotropen Glutamatrezeptoren (mGluR)
US8252810B2 (en) 2008-02-13 2012-08-28 Eisai R&D Management Co., Ltd. Bicycloamine derivatives
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
US8729083B2 (en) 2008-09-24 2014-05-20 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010059618A1 (en) * 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
JP2012532175A (ja) 2009-07-06 2012-12-13 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリダジン化合物
WO2011003796A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
EP2456308A2 (de) 2009-07-24 2012-05-30 Basf Se Pyridinderivate zur bekämpfung von wirbellosen schädlingen
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
WO2012139876A1 (en) 2011-04-14 2012-10-18 Merz Pharma Gmbh & Co. Kgaa Enteric formulations of metabotropic glutamate receptor modulators
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
RU2015106013A (ru) * 2012-08-10 2016-10-10 Ф. Хоффманн-Ля Рош Аг Соединения пиразолкарбоксамида, композиции и способы применения
HUE055618T2 (hu) 2012-12-07 2021-12-28 Vertex Pharma 2-amino-N-(piperidin-1-il-piridin-3-il)-pirazolo-[1,5-alfa]-pirimidin-3-karboxamid, mint atr-kináz inhibítoraként használható vegyület
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
EP2970289A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Als atr-kinaseinhibitoren nützliche verbindungen
EP2970288A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Als atr-kinaseinhibitoren nützliche verbindungen
EP2970286A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Kondensierte pyrazolopyrimidinderivate als inhibitoren der atr-kinase
WO2015048245A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
RU2020110358A (ru) 2014-06-05 2020-04-30 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
AU2017319080B2 (en) * 2016-08-31 2020-12-17 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyrimidine compound
EP3760631B1 (de) 2018-02-26 2023-11-08 Eisai R&D Management Co., Ltd. Kristall eines salzes der pyrazolo[1,5-a]pyrimidin-verbindung
WO2023141866A1 (en) * 2022-01-27 2023-08-03 Janssen Pharmaceutica Nv Pyrazolopyrimidines as modulators of spermine oxidase
US20230322792A1 (en) * 2022-04-08 2023-10-12 Biolexis Therapeutics, Inc. Cdk9 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) * 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
KR100315837B1 (ko) * 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
WO1996032394A1 (fr) * 1995-04-10 1996-10-17 Otsuka Pharmaceutical Factory, Inc. DERIVES DE PYRAZOLO[1,5-a]PYRIMIDINE
US5843951A (en) * 1995-09-28 1998-12-01 Otsuka Pharmaceutical Factory Inc. Analgesic composition of pyrazolo(1,5-A) pyrimidines
JP4000433B2 (ja) * 1998-01-29 2007-10-31 株式会社大塚製薬工場 ピラゾロ〔１，５−ａ〕ピリミジン誘導体
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AU4589701A (en) * 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
DE10112197A1 (de) * 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Pyrazolo- und Thiazolopyrimidine
DE10153344A1 (de) * 2001-10-29 2003-05-15 Gruenenthal Gmbh Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
CA2445515A1 (en) * 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Also Published As

Publication number Publication date
EP1506196B1 (de) 2012-01-18
CA2465326C (en) 2011-03-29
EP1506196A4 (de) 2008-01-02
WO2003037900A3 (en) 2004-11-18
US6833371B2 (en) 2004-12-21
US20050215569A1 (en) 2005-09-29
US20030176450A1 (en) 2003-09-18
US7098335B2 (en) 2006-08-29
EP1506196A2 (de) 2005-02-16
WO2003037900A2 (en) 2003-05-08
CA2465326A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
ATE541847T1 (de) Pyrazolopyrimidine als natriumkanalblocker
EP1451160A4 (de) Pyrazolamide und -sulfonamide
WO2003037890A3 (en) Piperidines
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
WO2009012242A3 (en) Sodium channel inhibitors
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
EP1463733A4 (de) Inhibitoren von mitotischem kinesin
DE60329990D1 (de) Mitotische kinesin-hemmer
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
WO2003039460A3 (en) Mitotic kinesin inhibitors
DE60329756D1 (de) Mitotische kinesin-hemmer
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MY151032A (en) Treatment of tnf? related disorders
ATE435214T1 (de) Als ionenkanalmodulatoren geeignete chinazoline
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
EP1515949A4 (de) Inhibitoren von mitotischem kinesin
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
AP2002002620A0 (en) Substituted arylpyrazines
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2004016221A3 (en) Sulfonamides as potassium channel blockers
SG157231A1 (en) Substituted p-diaminobenzene derivatives